Shafaat Ali Choyon.

Essay · Healthtech

The trust cold-start — how two-sided health platforms actually get going

By Md Shafaat Ali Choyon · builds & runs AI in production · Growth & health strategist · 6 min read

Every marketplace and platform faces the same terrifying first problem: nobody comes because nobody's there, and nobody's there because nobody comes. In health, that cold-start is harder than anywhere else, because the currency isn't only supply and demand — it's trust. And trust has its own cold-start: nobody trusts a platform until other people do.

The trust cold-start — health platforms die from lack of trust and liquidity, not features; seed density and trust first.
The cold-start, at a glance — click to enlarge.

The cold-start is a trust problem in disguise

Most platform post-mortems blame the product. The real killer is usually liquidity: too few of one side to make the other show up. In health you're stacking a trust cold-start on top of the liquidity one — a patient won't put their body in the hands of an empty, unproven platform, and a clinician won't lend their name to one either. Solve features all day; if you don't manufacture early trust and density, nothing moves.

I've solved this cold-start twice

At Praava I helped build a genuinely two-sided operation — patients on one side, doctors and corporate buyers on the other — and grew the corporate side from 342 to ~1,400 clients by seeding trust deliberately: proof, reliability, and reputation before scale. Earlier, I took the used-motorbike category on Ekhanei to No. 1 in two and a half months, which is a pure liquidity-and-trust problem — a stranger selling a stranger something neither can fully verify. Both worked the same way: concentrate, prove, densify, then expand.

A health platform doesn't die from a lack of features. It dies from a lack of trust and liquidity.

How you actually seed it

You don't launch broad; you launch dense. Pick one side, one segment, one geography, and over-serve it until the platform feels alive to a newcomer. Manufacture trust with proof — reviews, credentials, guarantees, a visible track record — and buy down the perceived risk of being early. Density in a narrow slice beats thin coverage everywhere, because liquidity and trust are both local before they're global.

The dual-market note

Emerging markets are pure cold-start laboratories — low baseline trust, thin infrastructure, no assumptions to coast on — which is exactly why building there teaches the mechanics so well. The same discipline that launches a marketplace in Dhaka launches a health platform in Ohio; the US just had more inherited trust to spend, and that cushion is thinning.

The short version

If your platform lost its features but kept its liquidity and trust, would it survive — and which of the three are you actually building first?

Md Shafaat Ali Choyon (MPH, CHES®, MBA, MCIM) is a growth, marketing and public-health strategist who builds and runs AI in production, with 16+ years across telecom, fintech, e-commerce, consumer tech and healthcare in the US and Bangladesh. See the essays or the portfolio.